- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00918047
Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients
June 29, 2017 updated by: Supernus Pharmaceuticals, Inc.
Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy
Study to evaluate the pharmacokinetics, safety, and tolerability of OXC XR as adjunctive therapy in pediatric subjects with refractory partial epilepsy.
Study Overview
Detailed Description
This was an open-label, multiple dose, multicenter study consisting of a Screening Period (up to 14 days), a Dosing Period (7 days), and a Follow-up Period (7 days).
In-clinic visits occurred at screening, Visit 1 (Day 0), and Visit 2 (Day 7)/Early Discontinuation.
All subjects received open-label SPN 804O as adjunctive therapy during the Dosing Period.
At Visit 1, eligible subjects were assigned to 1 of 4 treatment groups (150, 300, 450, or 600mg/day) based on weight (15-<30, 30-<45, 45-<60, >=60kg).
The Dosing Period consisted of six consecutive days of a daily dose, taken at home, followed by a final day with the dose taken on-site and including blood draws for PK analysis.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States
-
-
Florida
-
Loxahatchee Groves, Florida, United States
-
Tampa, Florida, United States
-
-
Maryland
-
Rockville, Maryland, United States
-
-
New York
-
Lake Success, New York, United States
-
Rochester, New York, United States
-
-
Tennessee
-
Kingsport, Tennessee, United States
-
-
Texas
-
San Antonio, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to provide written informed assent (IAF), as appropriate, with written informed permission (and informed consent (ICF) where required by regional laws or regulations) from the parent or legally-authorized representative (LAR).
- Male or female aged 4 to 17 years, inclusive, with a current diagnosis of partial onset seizures with or without secondarily generalized seizures as confirmed by the 1981 and 1989 International League Against Epilepsy Classifications).
- Currently receiving treatment with at least one and up to two anti-epileptic drugs (AEDs), excluding oxcarbazepine and phenytoin. AED therapy must have been initiated more than one month prior to Visit 1 and doses must be stable for at least two weeks prior to Visit 1. A vagal nerve stimulator implanted for at least six months and with parameters unchanged for at least one month prior to Visit 1 is allowed and not considered to be an AED. Magnet use is allowed.
- No diagnosis of a progressive neurological disorder based on previous imaging.
- Weight within the 25 - 75 % weight-for-age percentiles based on the National Center for Health Statistics Growth Charts, and not less than 15.0kg.
- Able and willing to swallow whole tablets.
Females of childbearing potential (FOCP) should either be sexually inactive (abstinent) for 14 days prior to the first dose, throughout the study and for four days following the last dose or, if sexually active, will be using one of the following acceptable birth control methods:
- Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) six months minimum;
- Intrauterine device in place for at least three months;
- Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the first dose, throughout the study and for four days following the last dose;
- Surgical sterilization of the partner (vasectomy for six months minimum);
- Hormonal contraceptives in addition to a barrier method (condom, diaphragm) with spermicide for at least 14 days prior to the first dose, throughout the study and for four days following the last dose.
Exclusion Criteria:
- A documented history of status epilepticus in the past year.
- Seizures secondary to illicit drug or alcohol use, infection, neoplasia, demyelinating disease, degenerative neurological disease, or central nervous system disease deemed progressive, metabolic illness, or progressive degenerative disease.
- Diagnosis or an electroencephalogram consistent with a diagnosis of seizure disorders other than partial epilepsy.
- Meets criteria for history of major depressive or manic episode, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.
- Any history of suicide intent and/or attempt.
- History or presence of clinically significant, chronic medical condition, especially those contraindicating antiseizure medication, (e.g., any neurological, gastrointestinal, endocrine, cardiovascular, pulmonary, hematological, immunologic, renal, hepatic or metabolic disease) that may affect the safety of the subject in the opinion of the Investigator.
- Use of oxcarbazepine or phenytoin within 10 days prior to first dose of SM.
- Use of felbamate with less than 18 months of continuous exposure prior to screening.
- Frequent need of rescue benzodiazepines (more than once in a 28 day period).
- Use of diuretics or other sodium-lowering medications within seven days prior to first dose of study medication (SM).
- History or presence of clinically significant laboratory, electrocardiogram (ECG), or vital sign abnormalities at screening that may affect the safety of the subject, in the opinion of the Investigator.
- Presence of potential hepatic function impairment as shown by, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN), or total bilirubin >1.5 times ULN.
- Presence of suspected impairment of renal function defined by serum creatinine ≥1.5 times ULN.
- History of substance abuse or dependence.
- Females who are pregnant or lactating.
- Previous known hypersensitivity to OXC or other related drugs, such as carbamazepine.
- Use of an investigational drug or device or participation in an investigational study within 30 days prior to the first dose of SM.
- Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SPN-804O 150mg/Day
Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day
|
Open Label study
Other Names:
|
Experimental: SPN-8040 300mg/Day
Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day
|
Open Label study
Other Names:
|
Experimental: SPN-8040 450mg/Day
Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day
|
Open Label study
Other Names:
|
Experimental: SPN-8040 600mg/Day
Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day
|
Open Label study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Examine the steady-state pharmacokinetics (PK) of OXC XR and to assess the safety and tolerability of repeated oral dosing of OXC XR in pediatric subjects with partial seizures.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
July 1, 2010
Study Completion (Actual)
November 1, 2010
Study Registration Dates
First Submitted
June 9, 2009
First Submitted That Met QC Criteria
June 10, 2009
First Posted (Estimate)
June 11, 2009
Study Record Updates
Last Update Posted (Actual)
July 2, 2017
Last Update Submitted That Met QC Criteria
June 29, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epilepsy
- Epilepsies, Partial
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Anticonvulsants
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Oxcarbazepine
Other Study ID Numbers
- 804P107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsies, Partial
-
UCB PharmaCompleted
-
UCB PharmaCompletedPartial EpilepsiesUnited States, Poland, United Kingdom, Switzerland, Hungary, Germany, Sweden, Lithuania
-
UCB BIOSCIENCES, Inc.CompletedPartial Epilepsies | Partial Onset SeizuresUnited States
-
UCB BIOSCIENCES, Inc.CompletedPartial EpilepsiesUnited States
-
UCB PharmaCompletedPartial EpilepsiesUnited States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
-
Institut National de la Santé Et de la Recherche...Unknown
-
UCB BIOSCIENCES, Inc.CompletedPartial Epilepsies | Partial Onset SeizuresUnited States
-
Vertex Pharmaceuticals IncorporatedTerminatedEpilepsyUnited States, Germany
-
Bial - Portela C S.A.Completed
-
GlaxoSmithKlineCompleted
Clinical Trials on SPN-804O
-
Supernus Pharmaceuticals, Inc.CompletedAttention-Deficit/Hyperactivity Disorder (ADHD)United States
-
Supernus Pharmaceuticals, Inc.Completed
-
Supernus Pharmaceuticals, Inc.Completed
-
Supernus Pharmaceuticals, Inc.Completed
-
Supernus Pharmaceuticals, Inc.Completed
-
University Hospital, GenevaUniversity of Lausanne HospitalsCompletedImpact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU PatientsCritically IllSwitzerland
-
Supernus Pharmaceuticals, Inc.CompletedConduct Disorder | Attention Deficit Disorder With HyperactivityUnited States
-
Supernus Pharmaceuticals, Inc.TerminatedAttention Deficit Hyperactivity DisorderUnited States
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive Aggression Comorbid With ADHDUnited States